Teva Pharmaceutical Industries Limited (TEVA) Sees Obstacles to Copying GlaxoSmithKline (GSK)'s Best-Selling Drug Advair Before 2018  
10/9/2013 8:04:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Teva Pharmaceuticals does not expect to see the launch of generic copies of GlaxoSmithKline's best-selling lung drug Advair that could be sold as a true substitute to U.S. patients before 2018. The cautious comments by the world's biggest maker of generic medicines during an investor presentation on Tuesday is good news for GSK shareholders, who had feared cheaper forms of the $8 billion-a-year seller might come around two years sooner. Deutsche Bank analysts said that pushing back generic competition to Advair by 18-24 months would boost GSK's mid- to long-term earnings outlook and give GSK more time to promote two newer respiratory drugs, Breo and Anoro.

Help employers find you! Check out all the jobs and post your resume.